Horizon Pharma has entered into a definitive agreement to acquire Hyperion Therapeutics, Inc. for approximately $1.1 billion in cash. The transaction, subject to customary conditions, is expected to close in 2Q15.   The transaction increases the number of Horizon’s products from five to seven, with the addition of RAVICTI and BUPHENYL to its orphan business unit. Sales of RAVICTI and BUPHENYL in 2014 were $113.6 million.   “The Hyperion acquisition will expand and diversify our produ...